Abstract

The idiopathic inflammatory myopathies (IIM) are a rare clinically heterogeneous group of conditions affecting the skin, muscle, joint, and lung in various combinations. While myositis specific autoantibodies are well described, we postulate that broader immune endotypes exist in IIM spanning B cell, T cell, and monocyte compartments. This study aims to identify immune endotypes through detailed immunophenotyping of peripheral blood mononuclear cells (PBMCs) in IIM patients compared to healthy controls. We collected PBMCs from 17 patients with a clinical diagnosis of inflammatory myositis and characterized the B, T, and myeloid cell subsets using mass cytometry by time of flight (CyTOF). Data were analyzed using a combination of the dimensionality reduction algorithm t-distributed stochastic neighbor embedding (t-SNE), cluster identification, characterization, and regression (CITRUS), and marker enrichment modeling (MEM); supervised biaxial gating validated populations identified by these methods to be differentially abundant between groups. Using these approaches, we identified shared immunologic features across all IIM patients, despite different clinical features, as well as two distinct immune endotypes. All IIM patients had decreased surface expression of RP105/CD180 on B cells and a reduction in circulating CD3+CXCR3+ subsets relative to healthy controls. One IIM endotype featured CXCR4 upregulation across all cellular compartments. The second endotype was hallmarked by an increased frequency of CD19+CD21loCD11c+ and CD3+CD4+PD1+ subsets. The experimental and analytical methods we describe here are broadly applicable to studying other immune-mediated diseases (e.g., autoimmunity, immunodeficiency) or protective immune responses (e.g., infection, vaccination).

Highlights

  • The idiopathic inflammatory myopathies (IIM) are a family of autoimmune diseases afflicting 2.4 to 33.8 per 100,000 individuals

  • We performed clinical phenotyping by chart abstraction to estimate the date of symptom onset and collected serologic data, including anti-nuclear antibodies (ANA), rheumatoid factor (RF), cyclic citrullinated peptide (CCP), and an extended myositis panel obtained through ARUP (Salt Lake City, UT), which included Jo-1, PL-7, PL-12, EJ, OJ, Ro52, Ro60, Ku, MDA5, Mi-2, NXP-2, P155/140, Pm/Scl 100, SAE-1/SUMO, SRP, Tif-1g, U1RNP, and U3RNP

  • We studied patients clinically diagnosed with IIM and healthy controls

Read more

Summary

Introduction

The idiopathic inflammatory myopathies (IIM) are a family of autoimmune diseases afflicting 2.4 to 33.8 per 100,000 individuals. IIM are associated with significant morbidity and mortality [1]. IIM patients have a three-fold increased risk of death [2], and 14% cannot dress independently [3]. IIM are quite heterogenous and causes varying degrees of skin rash, proximal muscle weakness, esophageal dysmotility, and interstitial lung disease (ILD). Mi-2 positive patients frequently manifest with classical rashes, mild to moderate muscle involvement, and rarely have ILD [15], whereas MDA5 positive patients have cutaneous ulcerations, arthritis, and progressive lung disease that can rapidly lead to death [14].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call